clinical trial · NCT07055607
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
Novo Nordisk A/S·—·enrolling by invitation·n = 1,250
ObesitySemaglutide
brief summary
This observational study will explore how Wegovy® (Semaglutide) is used in everyday situations, how it might affect things like weight, body mass index (BMI) and waist circumference, and what kind of impact it could have on overall quality of life. The overall purpose of this study is to understand how Wegovy impacts weight when used as part of regular medical care. Participants will be treated with Wegovy as prescribed to the participant by their doctor, in accordance with normal clinical practice. The study will last for about two years.
started
Nov 21, 2025
primary completion
Aug 15, 2028
completion
Aug 15, 2028
last updated
Mar 5, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol